Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC.
Richardson PG, et al. Among authors: miguel js.
Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.284325. Online ahead of print.
Haematologica. 2024.
PMID: 38299578
Free article.